Synthesis, Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) Activities, and Molecular Docking Studies of a Novel Compound Based on Combination of Flurbiprofen and Isoniazide

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35515452

Authors

Amina Asghar

Muhammad Yousuf

Ghulam Fareed

Rabia Nazir

Abida Hassan

Aneela Maalik

Tayyaba Noor

Naseem Iqbal

Lubna Rasheed

Affiliations

Soon will be listed here.

Abstract

Synthesis of a compound with balanced bioactivities against a specific target is always a challenging task. In this study, a novel compound (1) has been synthesized by combination of flurbiprofen and isoniazide and shows ∼2.5 times enhanced acetylcholinesterase (AChE) inhibition activity and ∼1.7 times improved butyrylcholinesterase (BuChE) inhibition activity compared to flurbiprofen and a standard drug ( physostigmine). A comparative AutoDock study has been performed, based on the optimized structure, by the DFT/B3LYP method, which confirmed that compound (1) is more active against AChE and BuChE, with calculated binding energies of -12.9 kcal mol and -9.8 kcal mol respectively as compared to flurbiprofen and an eserine (physostigmine) standard for which the binding energy was calculated to be -10.1 kcal mol and -8.9 kcal mol, respectively. A mixed mode of inhibition of AChE and BuChE with compound 1 was confirmed by Lineweaver-Burk plots. AChE and BuChE inhibition activity alongside docking results suggests that compound (1) could be used for treatment of Alzheimer's disease. Moreover, compound (1) also exhibit better α-chymotrypsin activity compared to flurbiprofen. Furthermore, and analysis confirmed that compound (1) exhibit more activity and less toxicity than the parent compounds.

Citing Articles

Gelatin/PLA-loaded gold nanocomposites synthesis using Syzygium cumini fruit extract and their antioxidant, antibacterial, anti-inflammatory, antidiabetic and anti-Alzheimer's activities.

Rajkumar M, Presley S, Thiyagarajulu N, Girigoswami K, Janani G, Kamaraj C Sci Rep. 2025; 15(1):2110.

PMID: 39814774 PMC: 11735676. DOI: 10.1038/s41598-024-84098-5.

Assessing the Potential of 1,2,3-Triazole-Dihydropyrimidinone Hybrids Against Cholinesterases: In Silico, In Vitro, and In Vivo Studies.

Gastalho C, Sena A, Lopez O, Fernandez-Bolanos J, Garcia-Sosa A, Pereira F Int J Mol Sci. 2024; 25(20).

PMID: 39456935 PMC: 11508620. DOI: 10.3390/ijms252011153.

Design of Promising Thiazoloindazole-Based Acetylcholinesterase Inhibitors Guided by Molecular Docking and Experimental Insights.

Laghchioua F, da Silva C, Pinto D, Cavaleiro J, Mendes R, Paz F ACS Chem Neurosci. 2024; 15(15):2853-2869.

PMID: 39037949 PMC: 11311138. DOI: 10.1021/acschemneuro.4c00241.

Chemoinformatics Study of Benzodiazepine-1, 2, 3-triazole Derivatives Targeting Butyrylcholinesterase.

El Allouche Y, Alaqarbeh M, El Aissouq A, El Rhabori S, Ech-Chahdi Y, Bouachrine M J Fluoresc. 2024; .

PMID: 38884828 DOI: 10.1007/s10895-024-03812-8.

Synthesis of biologically active cefpodoxime and vanillin-based schiff base metal complexes with the detailed biological evaluations.

Razaq N, Asghar A, Mumtaz A, Al-Mijalli S, Nisa M, Riaz T Biometals. 2024; 37(5):1201-1224.

PMID: 38864936 DOI: 10.1007/s10534-024-00601-5.

References

Morsy A, Trippier P . Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2019; 72(s1):S145-S176. DOI: 10.3233/JAD-190744. View

Mushtaq G, Greig N, Khan J, Kamal M . Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014; 13(8):1432-9. PMC: 5878042. DOI: 10.2174/1871527313666141023141545. View

Bacalhau P, San Juan A, Marques C, Peixoto D, Goth A, Guarda C . New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives. Bioorg Chem. 2016; 67:1-8. DOI: 10.1016/j.bioorg.2016.05.004. View

Inotai A, Hanko B, Meszaros A . Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf. 2009; 19(2):183-90. DOI: 10.1002/pds.1893. View

Vane J . The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol. 2001; 51(4 Pt 1):573-86. View

Talley J . Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Med Chem. 2000; 36:201-34. DOI: 10.1016/s0079-6468(08)70048-1. View

Bourne Y, Taylor P, Radic Z, Marchot P . Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J. 2002; 22(1):1-12. PMC: 140045. DOI: 10.1093/emboj/cdg005. View

Prasit P, Wang Z, Brideau C, Chan C, Charleson S, Cromlish W . The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett. 1999; 9(13):1773-8. DOI: 10.1016/s0960-894x(99)00288-7. View

Ciro A, Park J, Burkhard G, Yan N, Geula C . Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex. Curr Alzheimer Res. 2011; 9(1):138-43. PMC: 3279606. DOI: 10.2174/156720512799015127. View

10.

Stierand K, Rarey M . Drawing the PDB: Protein-Ligand Complexes in Two Dimensions. ACS Med Chem Lett. 2014; 1(9):540-5. PMC: 4007829. DOI: 10.1021/ml100164p. View

11.

Asghar A, Yousuf M, Mubeen H, Nazir R, Haruna K, Onawole A . Synthesis, spectroscopic characterization, molecular docking and theoretical studies (DFT) of N-(4-aminophenylsulfonyl)-2-(4-isobutylphenyl) propanamide having potential enzyme inhibition applications. Bioorg Med Chem. 2019; 27(12):2397-2404. DOI: 10.1016/j.bmc.2019.01.012. View

12.

Panek D, Wieckowska A, Jonczyk J, Godyn J, Bajda M, Wichur T . Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents. ACS Chem Neurosci. 2018; 9(5):1074-1094. DOI: 10.1021/acschemneuro.7b00461. View

13.

Perry E, Perry R, Blessed G, Tomlinson B . Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978; 4(4):273-7. DOI: 10.1111/j.1365-2990.1978.tb00545.x. View

14.

Whitehouse P, Price D, Struble R, CLARK A, Coyle J, Delon M . Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982; 215(4537):1237-9. DOI: 10.1126/science.7058341. View

15.

Andres A, Roses M, Rafols C, Bosch E, Espinosa S, Segarra V . Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. Eur J Pharm Sci. 2015; 76:181-91. DOI: 10.1016/j.ejps.2015.05.008. View

16.

Zhang Y, Guo Z, You X . Hydrolysis theory for cisplatin and its analogues based on density functional studies. J Am Chem Soc. 2001; 123(38):9378-87. DOI: 10.1021/ja0023938. View

17.

Yousuf M, Youn I, Yun J, Rasheed L, Valero R, Shi G . Violation of DNA neighbor exclusion principle in RNA recognition. Chem Sci. 2018; 7(6):3581-3588. PMC: 6007354. DOI: 10.1039/c5sc03740a. View

18.

Bajda M, Guzior N, Ignasik M, Malawska B . Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem. 2011; 18(32):4949-75. DOI: 10.2174/092986711797535245. View

19.

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

20.

Sussman J, Harel M, Frolow F, Oefner C, Goldman A, Toker L . Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 1991; 253(5022):872-9. DOI: 10.1126/science.1678899. View